EP1626717A4 - Benzimidazoles, compositions containing such compounds and methods of use - Google Patents
Benzimidazoles, compositions containing such compounds and methods of useInfo
- Publication number
- EP1626717A4 EP1626717A4 EP04751318A EP04751318A EP1626717A4 EP 1626717 A4 EP1626717 A4 EP 1626717A4 EP 04751318 A EP04751318 A EP 04751318A EP 04751318 A EP04751318 A EP 04751318A EP 1626717 A4 EP1626717 A4 EP 1626717A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzimidazoles
- compounds
- methods
- compositions containing
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46933203P | 2003-05-09 | 2003-05-09 | |
PCT/US2004/013874 WO2004100875A2 (en) | 2003-05-09 | 2004-05-05 | Benzimidazoles, compositions containing such compounds and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1626717A2 EP1626717A2 (en) | 2006-02-22 |
EP1626717A4 true EP1626717A4 (en) | 2009-09-09 |
Family
ID=33452275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04751318A Withdrawn EP1626717A4 (en) | 2003-05-09 | 2004-05-05 | Benzimidazoles, compositions containing such compounds and methods of use |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1626717A4 (en) |
JP (1) | JP2006528687A (en) |
CN (1) | CN1784226A (en) |
AU (1) | AU2004238240A1 (en) |
CA (1) | CA2524436A1 (en) |
WO (1) | WO2004100875A2 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE490244T1 (en) | 2003-01-27 | 2010-12-15 | Merck Sharp & Dohme | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE |
CA2540845C (en) * | 2003-10-02 | 2010-11-09 | Schering Corporation | Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
AU2005252183B2 (en) * | 2004-06-04 | 2008-07-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives, compositions containing such compounds and methods of use |
DE602005021494D1 (en) | 2004-07-22 | 2010-07-08 | Merck Sharp & Dohme | SUBSTITUTED PYRAZOLE, SUCH COMPOUNDS AND COMPOSITIONS AND METHOD OF USE THEREOF |
CA2614544C (en) | 2005-07-13 | 2013-09-10 | Banyu Pharmaceutical Co., Ltd. | Heterocycle-substituted benzimidazole derivative |
US7709658B2 (en) | 2005-07-26 | 2010-05-04 | Merck Sharp & Dohme Corp. | Process for synthesizing a substituted pyrazole |
NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
TW200745031A (en) * | 2005-10-13 | 2007-12-16 | Merck & Co Inc | Acyl indoles, compositions containing such compounds and methods of use |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
ES2720430T3 (en) | 2007-02-09 | 2019-07-22 | Metabasis Therapeutics Inc | Novel glucagon receptor antagonists |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
KR101616140B1 (en) * | 2008-03-05 | 2016-04-27 | 다케다 야쿠힌 고교 가부시키가이샤 | Heterocyclic compound |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010019830A1 (en) | 2008-08-13 | 2010-02-18 | Metabasis Therapeutics, Inc. | Glucagon antagonists |
JP5764064B2 (en) * | 2008-09-26 | 2015-08-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
TWI475018B (en) * | 2009-02-06 | 2015-03-01 | Takeda Pharmaceutical | Heterocyclic compound |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011027849A1 (en) * | 2009-09-04 | 2011-03-10 | 武田薬品工業株式会社 | Heterocyclic compound |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
NZ611529A (en) | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
HUE030364T2 (en) | 2011-02-08 | 2017-04-28 | Pfizer | Glucagon receptor modulator |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683701B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use |
EP2683698B1 (en) | 2011-03-08 | 2017-10-04 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
KR20140023441A (en) | 2011-07-22 | 2014-02-26 | 화이자 인코포레이티드 | Quinolinyl glucagon receptor modulators |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3154956A4 (en) | 2014-06-12 | 2018-01-17 | Ligand Pharmaceuticals, Inc. | Glucagon antagonists |
JP2021513564A (en) | 2018-02-13 | 2021-05-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Glucagon receptor antagonist |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069810A1 (en) * | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1069124A1 (en) * | 1999-07-16 | 2001-01-17 | Pfizer Inc. | 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705515A (en) * | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
-
2004
- 2004-05-05 JP JP2006532564A patent/JP2006528687A/en not_active Withdrawn
- 2004-05-05 CN CNA2004800124899A patent/CN1784226A/en active Pending
- 2004-05-05 AU AU2004238240A patent/AU2004238240A1/en not_active Abandoned
- 2004-05-05 CA CA002524436A patent/CA2524436A1/en not_active Abandoned
- 2004-05-05 WO PCT/US2004/013874 patent/WO2004100875A2/en active Application Filing
- 2004-05-05 EP EP04751318A patent/EP1626717A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069810A1 (en) * | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1069124A1 (en) * | 1999-07-16 | 2001-01-17 | Pfizer Inc. | 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
Non-Patent Citations (1)
Title |
---|
R. M. KIM ET AL.: "Discovery of potent, orally active benzimidazole glucagon receptor antagonists", BIOORG. MED. CHEM. LETT., vol. 18, no. 13, 22 May 2008 (2008-05-22), pages 3701 - 3705, XP002537989 * |
Also Published As
Publication number | Publication date |
---|---|
EP1626717A2 (en) | 2006-02-22 |
JP2006528687A (en) | 2006-12-21 |
AU2004238240A1 (en) | 2004-11-25 |
CN1784226A (en) | 2006-06-07 |
WO2004100875A2 (en) | 2004-11-25 |
WO2004100875A3 (en) | 2005-03-17 |
CA2524436A1 (en) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1626717A4 (en) | Benzimidazoles, compositions containing such compounds and methods of use | |
IL179754A0 (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
IL173044A0 (en) | Aryl and heteroaryl compounds, compositions, and methods of use | |
EP1699453A4 (en) | Cyclic guanidines, compositions containing such compounds and methods of use | |
IL175300A0 (en) | Indirubin-type compounds, compositions, and methods for their use | |
HK1083835A1 (en) | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | |
EP1646382A4 (en) | Compounds, compositions and methods | |
HRP20040665B1 (en) | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | |
EP1692112A4 (en) | Compounds, compositions, and methods | |
IL176571A0 (en) | Substituted azole derivatives, compositions, and methods of use | |
GB0307891D0 (en) | Chemical compounds,compositions and uses | |
HK1089436A1 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
HK1090639A1 (en) | Immunosuppressant compounds and compositions | |
EP1633336A4 (en) | Immunosuppressant compounds and compositions | |
GB0323845D0 (en) | Chemical compounds,compositions and uses | |
IL172023A0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
HK1086485A1 (en) | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | |
IL172027A0 (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
IL190477A0 (en) | Pyrazole derivatives, compositions containing such compounds and methods of use | |
EP1651231A4 (en) | Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use | |
HUP0500871A3 (en) | 5-aryltetrazole compounds, compositions thereof and their use | |
IL179530A0 (en) | Novel compounds, pharmaceutical compositions containing same and methods of use for same | |
EP1663255A4 (en) | Withanamide and withanolide compositions and method of use thereof | |
EP1675834A4 (en) | Compounds, compositions, and methods | |
EP1594849A4 (en) | Compounds, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051209 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: LT LV |
|
RAX | Requested extension states of the european patent have changed |
Extension state: LV Payment date: 20051209 Extension state: LT Payment date: 20051209 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090806 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20091218 |